ANKARA, Nov 25 — A leading Chinese company on Wednesday announced it has sought formal approval from authorities to bring its COVID-19 vaccine to the market, Anadolu Agency reported according to state-run media.
Sinopharm’s vice-general manager Shi Shengyi said the company has collected data from major countries carrying out its vaccine’s clinical trials and the results are expected to be favourable, Global Times reported.
Earlier, the company said that it had submitted the vaccine’s Phase-3 clinical data to China’s State Food and Drug Administration and was in the process of giving more detailed data.
The company said it is in the final stage before marketisation and is now making approval of the vaccine its top priority.
The company is expected to release its vaccine’s Phase-3 data after the government approval.
“Our data is evaluated by relevant departments following protocols even stricter than in some Western countries, and we are in close communication with the WHO,” the company representative further said.
Last month, China claimed that its experimental vaccines for protection against COVID-19 have shown “no adverse reaction”.
According to Chinese officials, the country has 13 vaccine candidates entering clinical trials, including four in Phase-3 trials.
Over 100 vaccines to prevent coronavirus are at different stages of development. The US drug maker Pfizer and German biotech company BioNTech last week said that their coronavirus vaccine is 95 per cent effective, upgrading an earlier estimate of 90 per cent.
Their announcement came days after US drug company Moderna said its own shot was 94.5 per cent effective.